conivaptan has been researched along with bosentan anhydrous in 4 studies
Studies (conivaptan) | Trials (conivaptan) | Recent Studies (post-2010) (conivaptan) | Studies (bosentan anhydrous) | Trials (bosentan anhydrous) | Recent Studies (post-2010) (bosentan anhydrous) |
---|---|---|---|---|---|
188 | 17 | 64 | 1,836 | 215 | 630 |
Protein | Taxonomy | conivaptan (IC50) | bosentan anhydrous (IC50) |
---|---|---|---|
Endothelin receptor type B | Rattus norvegicus (Norway rat) | 0.095 | |
Endothelin receptor type B | Homo sapiens (human) | 0.3044 | |
Endothelin-1 receptor | Homo sapiens (human) | 0.2317 | |
Endothelin-1 receptor | Rattus norvegicus (Norway rat) | 0.0047 | |
Endothelin-1 receptor | Sus scrofa (pig) | 0.0075 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Cherubini, A; Di Lenarda, A; Perkan, A; Salvatore, L; Sinagra, G | 1 |
Dhalla, NS; Rehsia, NS | 1 |
3 review(s) available for conivaptan and bosentan anhydrous
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Treatment of heart failure: an update].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Benzazepines; Bosentan; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Defibrillators, Implantable; Double-Blind Method; Heart Failure; Heart-Assist Devices; Humans; Metoprolol; Multicenter Studies as Topic; Placebos; Propanolamines; Prospective Studies; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Sulfonamides; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2002 |
Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.
Topics: Angiotensin II; Animals; Antidiuretic Agents; Antihypertensive Agents; Benzazepines; Biomarkers; Bosentan; Catecholamines; Drug Therapy, Combination; Endothelin-1; Heart Failure; Humans; Peptides, Cyclic; Renin-Angiotensin System; Sulfonamides; Sympathetic Nervous System; Tolvaptan; Treatment Outcome; Vasopressins | 2010 |
1 other study(ies) available for conivaptan and bosentan anhydrous
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |